NCT02045589View on ClinicalTrials.gov

A Phase I Dose Escalation Study of Intratumoral VCN-01 Injections With Gemcitabine and Abraxane® in Patients With Advanced Pancreatic Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

October 31, 2016

Study Completion Date

September 30, 2018

Conditions

Pancreatic AdenocarcinomaMetastatic Pancreatic Adenocarcinoma

Interventions

GENETIC

VCN-01

Genetically modified human adenovirus encoding human PH20 hyaluronidase

DRUG

Gemcitabine

1000 mg/m2 intravenous administration

DRUG

Abraxane®

125 mg/m2 intravenous administration

Trial Locations (3)

25080

Centro Integral Oncológico Clara Campal, Madrid

28041

Hospital Universitario 12 de Octubre, Madrid

08908

Institut Català d'Oncologia, L'Hospitalet de Llobregat

All Listed Sponsors

lead

Theriva Biologics SL

INDUSTRY

NCT02045589 - A Phase I Dose Escalation Study of Intratumoral VCN-01 Injections With Gemcitabine and Abraxane® in Patients With Advanced Pancreatic Cancer | Biotech Hunter | Biotech Hunter